Smoking cessation drug linked to cardiovascular adverse events

In a study of new varenicline users, researchers found that the incidence of cardiovascular events was 34% higher during the 12-week treatment period than in the year before or after use
Source: Clinical Pharmacist - Category: Drugs & Pharmacology Source Type: research